No Data
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
HC Wainwright & Co. Initiates Coverage On Arcutis Biotherapeutics With Buy Rating, Announces Price Target of $19
Arcutis Biotherapeutics Analyst Ratings
Top-rated Smaller Defensive Stocks After Societe Generale Permabear Takes Contrarian View
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Virtus LifeSci Biotech Clinical Trials ETF Declares Annual Distribution of $0.2394